Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?

Core Viewpoint - Supernus Pharmaceuticals has shown strong stock performance, with a 36.9% increase year-to-date, significantly outperforming the Zacks Medical sector and the Zacks Medical - Generic Drugs industry [1][2]. Financial Performance - Supernus has consistently exceeded earnings expectations, reporting an EPS of $0.91 against a consensus estimate of $0.47 in its last earnings report [2]. - For the current fiscal year, Supernus is projected to achieve earnings of $2.24 per share on revenues of $696.95 million, reflecting a -28.34% change in EPS and a 5.31% change in revenues. The next fiscal year is expected to see earnings of $2.31 per share on revenues of $843.62 million, indicating a year-over-year change of 2.89% in EPS and 21.05% in revenues [3]. Valuation Metrics - Supernus currently trades at 22.1 times the current fiscal year EPS estimates, which is a premium compared to the peer industry average of 8.2 times. On a trailing cash flow basis, it trades at 11.9 times versus the peer group's average of 5.7 times [6]. Style Scores and Zacks Rank - Supernus has a Value Score of C, a Growth Score of C, and a Momentum Score of A, resulting in a VGM Score of B. The Zacks Rank for Supernus is 1 (Strong Buy), supported by favorable earnings estimate revisions from analysts [5][7].